Please login to the form below
Skyrizi
This page shows the latest Skyrizi news and features for those working in and with pharma, biotech and healthcare.
Lilly reports positive data from its phase 3 ulcerative colitis trial
For Crohn’s, mirikizumab is in a close race with AbbVie’s IL-23 inhibitor Skyrizi (risankizumab), which recently met both primary endpoints of clinical remission and endoscopic response at week ... Skyrizi is also being evaluated in a phase 2/3
Latest news
-
AbbVie/Allergan merger faces renewed public opposition despite divestments
AbbVie. They also highlighted AbbVie’s use of controversial “rebate walls” around its blockbuster immunology products – including Humira and Skyrizi – which the groups say “lead to higher prescription drug prices” and
-
Skyrizi, Rinvoq help AbbVie weather Humira slowdown
news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well ... IL-23 antagonist Skyrizi for psoriasis did particularly
-
Cosentyx, Entresto drive topline growth for Novartis in Q4
However, in head-to-head trials with both AbbVie’s Humira (adalimumab) and Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market
-
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
Skyrizi also met a non-inferiority endpoint at 16 weeks, with 74% of patients achieving PASI 90 versus 66% for Cosentyx. ... Skyrizi meanwhile only needs to be dosed every 12 weeks after an initial loading phase.
-
AbbVie creates new aesthetics division amid Allergan takeover
This includes psoriasis treatment Skyrizi, Rinvoq, medical Botox, and cancer treatments Imbruvica and Veclexta.
AbbVie/Allergan merger faces renewed public opposition despite divestments
Cosentyx, Entresto drive topline growth for Novartis in Q4
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
AbbVie creates new aesthetics division amid Allergan takeover
More from news
Approximately 8 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Developed by Boehringer Ingelheim and AbbVie, Skyrizi is a monoclonal antibody that inhibits the pro-inflammatory cytokine IL-23. ... Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy.
20 for 2020 – Five pharma companies to watch
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Assessing the value of interim analyses in clinical trials
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- AZ’s Imfinzi combination shows promise in liver cancer
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Novo Nordisk settles US insulin pricing dispute for $100m
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- bluebird bio provides update on 2seventy bio spin-off
- Amgen strikes $240m autoimmune deal with Evoq Therapeutics
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
